Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Struggling Merck Serono Pins Hopes On New Management, Organization

This article was originally published in The Pink Sheet Daily

Executive Summary

One-time charges hit second quarter results; new management brought in to improve margins and productivity.

You may also be interested in...



Threshold Presses On In Two Phase III Cancer Trials As Competitors Wilt

Threshold and partner Merck Serono are benefiting from recent high-profile failures in sarcoma and pancreatic cancer. Armed with $100 million in payments since signing with Merck in February 2012, Threshold needs to rise above stiff odds and what some view as equivocal Phase II pancreatic cancer results.

Diversification Fails To Protect Merck KGaA From Industry Pressures

Merck KGaA plans to cut headcount and reduce costs, although employees are to be asked first to identify pragmatic cost-saving strategies.

Merck KGaA Plays On Multiple Initiatives; Aims For 30% Growth In Emerging Markets

MUMBAI - Contrary to what most global CEOs would say about challenges confronting the global pharmaceutical industry, Karl-Ludwig Kley, chairman of the $12.28 billion German chemicals and pharmaceuticals conglomerate Merck KGaA, says he doesn't believe the pharma business model is broken, despite dwindling R&D pipelines, increasing spend and diving sales as fewer blockbusters make it to market

Related Content

Topics

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel